மூத்தவர் ஆசிரிய இணை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மூத்தவர் ஆசிரிய இணை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மூத்தவர் ஆசிரிய இணை Today - Breaking & Trending Today

Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates

Share this article
LA JOLLA, Calif., March 9, 2021 /PRNewswire/
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the Company or Regulus ), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.
Regulus finished the year on a high note , stated Jay Hagan, CEO of Regulus. We advanced RGLS4326 into a Phase 1b study in ADPKD patients, achieved an enrollment milestone for RG-012 with Sanofi and its Phase 2 clinical study for the treatment of patients with Alport syndrome, and completed a private financing. With the recent progress, we believe we are well positioned to advance the ADPKD program through Phase 1b while also advancing our next generation ADPKD compound toward the clinic. ....

United States , Alice Huang , Jay Hagan , Rnas The Company Or Regulus , Company Board Of Directors , Regulus Therapeutics Inc , Harvard Medical School , Exchange Commission , Development Rd Expenses , California Institute Of Technology , Enterprise Associates , Company Board , York University , Program Updates , License Agreement , Private Financing , Common Stock , New Enterprise Associates , Senior Faculty Associate , Biological Engineering , California Institute , New York University , Molecular Genetics , Infectious Disease , Boston Children , Partial Clinical Hold ,

Regulus Announces Addition to Board of Directors

Regulus Announces Addition to Board of Directors
News provided by
Share this article
LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Company s board of directors. Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee.
We are pleased to add Dr. Huang to the Regulus board. We believe her extensive scientific background will be of benefit to helping direct the Company s drug discovery and development programs, said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus. ....

United States , University Of Massachusetts , Stelios Papadopoulos , Alices Huang , Johns Hopkins University , National Foundation For Infectious Diseases , National Cancer Institute , Health Effects Institute , Compensation Committee , American Association For The Advancement Of Science , American Academy Of Microbiology , Food Drug Administration , Us Army Medical Research Development , Schlesinger Library At Radcliffe Institute , Regulus Therapeutics Inc , American Association Of Women , California Institute Of Technology , Molecular Genetics At Harvard Medical School , Rockefeller Foundation , Professor Of Biology At New York University , Regulus Therapeutics , Senior Faculty Associate , Biological Engineering , California Institute , New York University , Molecular Genetics ,